Published in J Infect Dis on January 17, 2002
Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis (2014) 4.24
History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev (2004) 3.40
Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med (2009) 3.38
Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci U S A (2009) 3.30
A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J (2009) 2.64
Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob Agents Chemother (2003) 2.57
Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci U S A (2009) 2.57
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. Clin Infect Dis (2012) 2.19
High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS One (2009) 2.18
The evolution of drug-resistant malaria. Trans R Soc Trop Med Hyg (2008) 2.17
Selection strength and hitchhiking around two anti-malarial resistance genes. Proc Biol Sci (2005) 2.04
Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with sulfadoxine-pyrimethamine resistance. Antimicrob Agents Chemother (2004) 2.04
Origin and evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathog (2010) 1.96
Decreasing burden of malaria in pregnancy in Malawian women and its relationship to use of intermittent preventive therapy or bed nets. PLoS One (2010) 1.73
Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility. Antimicrob Agents Chemother (2009) 1.70
Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrob Agents Chemother (2005) 1.69
Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. J Infect Dis (2011) 1.68
Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ (2011) 1.62
Pyrosequencing, a high-throughput method for detecting single nucleotide polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum. J Clin Microbiol (2006) 1.61
Drug-resistant malaria - an insight. FEBS J (2007) 1.54
Molecular epidemiology of malaria. Clin Microbiol Rev (2007) 1.53
Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems. Lancet Infect Dis (2012) 1.53
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nat Chem Biol (2009) 1.52
Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malar J (2012) 1.45
Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS One (2007) 1.44
A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women. PLoS One (2007) 1.38
Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. Antimicrob Agents Chemother (2005) 1.35
Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal. Trop Med Int Health (2005) 1.34
Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987--2006. J Infect Dis (2008) 1.32
Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review. PLoS One (2013) 1.29
Drug resistance maps to guide intermittent preventive treatment of malaria in African infants. Parasitology (2011) 1.28
High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia. Malar J (2006) 1.27
Genetic structure of Plasmodium falciparum and elimination of malaria, Comoros archipelago. Emerg Infect Dis (2010) 1.27
Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania. Emerg Infect Dis (2013) 1.26
A database of antimalarial drug resistance. Malar J (2006) 1.24
Detection of the dihydrofolate reductase-164L mutation in Plasmodium falciparum infections from Malawi by heteroduplex tracking assay. Am J Trop Med Hyg (2008) 1.23
Adaptive evolution and fixation of drug-resistant Plasmodium falciparum genotypes in pregnancy-associated malaria: 9-year results from the QuEERPAM study. Infect Genet Evol (2011) 1.21
The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women. J Infect Dis (2015) 1.20
Prevalence of pfmdr1, pfcrt, pfdhfr and pfdhps mutations associated with drug resistance, in Luanda, Angola. Malar J (2008) 1.20
Field-based evidence of fast and global increase of Plasmodium falciparum drug-resistance by DNA-microarrays and PCR/RFLP in Niger. Malar J (2009) 1.19
Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants. PLoS One (2010) 1.19
Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine. Malar J (2010) 1.19
Molecular correlates of high-level antifolate resistance in Rwandan children with Plasmodium falciparum malaria. Antimicrob Agents Chemother (2009) 1.17
Prevalence of mutations associated with higher levels of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Car Nicobar Island and Assam, India. Antimicrob Agents Chemother (2006) 1.16
Quadruple mutations in dihydrofolate reductase of Plasmodium falciparum isolates from Car Nicobar Island, India. Antimicrob Agents Chemother (2006) 1.15
Drug susceptibility and genetic evaluation of Plasmodium falciparum isolates obtained in four distinct geographical regions of Kenya. Antimicrob Agents Chemother (2004) 1.15
Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis (2013) 1.15
Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis (2009) 1.14
Sulfadoxine-pyrimethamine impairs Plasmodium falciparum gametocyte infectivity and Anopheles mosquito survival. Int J Parasitol (2010) 1.14
Genetic structure of Plasmodium falciparum populations between lowland and highland sites and antimalarial drug resistance in Western Kenya. Infect Genet Evol (2009) 1.14
Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon. Malar J (2010) 1.11
Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America. Malar J (2011) 1.11
Spatiotemporal mathematical modelling of mutations of the dhps gene in African Plasmodium falciparum. Malar J (2013) 1.11
Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy. Trends Parasitol (2005) 1.11
Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar J (2009) 1.11
Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum. Malar J (2007) 1.10
Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya. Malar J (2010) 1.10
dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo. Trop Med Int Health (2008) 1.10
Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali. Int J Parasitol (2010) 1.10
Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique. Malar J (2008) 1.09
Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. PLoS One (2008) 1.09
Fitness trade-offs in the evolution of dihydrofolate reductase and drug resistance in Plasmodium falciparum. PLoS One (2011) 1.08
Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant. Malar J (2007) 1.07
Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy. Clin Microbiol Rev (2004) 1.06
High prevalence of markers for sulfadoxine and pyrimethamine resistance in Plasmodium falciparum in the absence of drug pressure in the Ashanti region of Ghana. Antimicrob Agents Chemother (2005) 1.06
Molecular surveillance of drug resistance through imported isolates of Plasmodium falciparum in Europe. Malar J (2002) 1.04
Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal. Parasitol Res (2011) 1.04
A multiplex ligase detection reaction-fluorescent microsphere assay for simultaneous detection of single nucleotide polymorphisms associated with Plasmodium falciparum drug resistance. J Clin Microbiol (2006) 1.04
Molecular epidemiology of drug-resistant malaria in western Kenya highlands. BMC Infect Dis (2008) 1.04
Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS One (2010) 1.04
The evolutionary landscape of antifolate resistance in Plasmodium falciparum. J Genet (2011) 1.01
Molecular characterization of antifolates resistance-associated genes, (dhfr and dhps) in Plasmodium vivax isolates from the Middle East. Malar J (2009) 1.01
Sulfadoxine-pyrimethamine resistance in the rodent malaria parasite Plasmodium chabaudi. Antimicrob Agents Chemother (2002) 1.01
Polymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 associated with resistance to sulfadoxine-pyrimethamine treatment. Antimicrob Agents Chemother (2009) 1.01
High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. Malar J (2013) 1.01
Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania. Malar J (2007) 1.00
Parasite clearance following treatment with sulphadoxine-pyrimethamine for intermittent preventive treatment in Burkina-Faso and Mali: 42-day in vivo follow-up study. Malar J (2014) 0.98
Malaria antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (DHFR) polymorphisms in humans and Anopheles mosquitoes. Proc Natl Acad Sci U S A (2011) 0.98
Island-wide diversity in single nucleotide polymorphisms of the Plasmodium vivax dihydrofolate reductase and dihydropteroate synthetase genes in Sri Lanka. Malar J (2007) 0.98
A molecular surveillance system for global patterns of drug resistance in imported malaria. Emerg Infect Dis (2003) 0.97
Development of a TaqMan Allelic Discrimination assay for detection of single nucleotides polymorphisms associated with anti-malarial drug resistance. Malar J (2012) 0.96
Genetic confirmation of quinine-resistant Plasmodium falciparum malaria followed by postmalaria neurological syndrome in a traveler from Mozambique. J Clin Microbiol (2004) 0.96
Comparative efficacies of artemisinin combination therapies in Plasmodium falciparum malaria and polymorphism of pfATPase6, pfcrt, pfdhfr, and pfdhps genes in tea gardens of Jalpaiguri District, India. Antimicrob Agents Chemother (2012) 0.96
Malaria epidemic and drug resistance, Djibouti. Emerg Infect Dis (2005) 0.96
High frequency of Plasmodium falciparum CICNI/SGEAA and CVIET haplotypes without association with resistance to sulfadoxine/pyrimethamine and chloroquine combination in the Daraweesh area, in Sudan. Eur J Clin Microbiol Infect Dis (2008) 0.95
Evaluation of prevalence's of pfdhfr and pfdhps mutations in Angola. Malar J (2011) 0.95
Surveillance of molecular markers of Plasmodium falciparum resistance to sulphadoxine-pyrimethamine 5 years after the change of malaria treatment policy in Ghana. Am J Trop Med Hyg (2012) 0.94
Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania. Malar J (2006) 0.93
Molecular epidemiology of drug resistance markers of Plasmodium falciparum in Yunnan Province, China. Malar J (2012) 0.93
Lack of effect of intermittent preventive treatment for malaria in pregnancy and intense drug resistance in western Uganda. Malar J (2015) 0.93
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med (2010) 8.51
Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med (2006) 7.70
Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med (2004) 7.42
A research agenda to underpin malaria eradication. PLoS Med (2011) 5.34
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis (2003) 5.21
Severe anemia in Malawian children. N Engl J Med (2008) 5.20
Malarial retinopathy: a newly established diagnostic sign in severe malaria. Am J Trop Med Hyg (2006) 5.14
Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. Lancet (2002) 4.90
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
The threat of artemisinin-resistant malaria. N Engl J Med (2011) 4.15
Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A (2012) 4.10
Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev (2005) 4.04
Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Res (2009) 3.99
Epidemics of invasive Salmonella enterica serovar enteritidis and S. enterica Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi. Clin Infect Dis (2008) 3.89
Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet (2005) 3.48
Blantyre Malaria Project Epilepsy Study (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors: a prospective cohort study. Lancet Neurol (2010) 3.47
A field trial to assess a blood-stage malaria vaccine. N Engl J Med (2011) 3.20
Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis (2007) 3.19
Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol (2008) 3.04
The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg (2004) 3.00
Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults. Science (2010) 2.91
Short report: Piloting paperless data entry for clinical research in Africa. Am J Trop Med Hyg (2005) 2.85
Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. AIDS (2002) 2.83
Placental monocyte infiltrates in response to Plasmodium falciparum malaria infection and their association with adverse pregnancy outcomes. Am J Trop Med Hyg (2003) 2.76
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One (2008) 2.70
Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria. J Infect Dis (2003) 2.70
Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet (2012) 2.69
Perfusion abnormalities in children with cerebral malaria and malarial retinopathy. J Infect Dis (2009) 2.69
Prognostic significance and course of retinopathy in children with severe malaria. Arch Ophthalmol (2004) 2.60
Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis (2002) 2.54
A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV. J Acquir Immune Defic Syndr (2005) 2.47
Endemic malaria in the Peruvian Amazon region of Iquitos. Am J Trop Med Hyg (2003) 2.43
Species identification after treatment for human taeniasis. Lancet (2004) 2.43
Syndromic surveillance: adapting innovations to developing settings. PLoS Med (2008) 2.38
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin (2010) 2.36
Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood (2013) 2.35
The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children. J Clin Invest (2008) 2.35
Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. AIDS (2006) 2.34
Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. Lancet Infect Dis (2011) 2.32
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med (2010) 2.30
Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 2.29
Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia. Mol Biochem Parasitol (2006) 2.22
Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis (2006) 2.22
Rabies encephalitis in malaria-endemic area, Malawi, Africa. Emerg Infect Dis (2007) 2.21
Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. Clin Infect Dis (2012) 2.19
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine (2005) 2.18
Plasma concentrations of parasite histidine-rich protein 2 distinguish between retinopathy-positive and retinopathy-negative cerebral malaria in Malawian children. J Infect Dis (2012) 2.16
High pneumococcal DNA loads are associated with mortality in Malawian children with invasive pneumococcal disease. Pediatr Infect Dis J (2007) 2.10
Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A (2007) 2.07
Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis. J Infect Dis (2009) 2.06
Community permission for medical research in developing countries. Clin Infect Dis (2005) 2.01
The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women. AIDS (2004) 2.01
Genome-wide SNP genotyping highlights the role of natural selection in Plasmodium falciparum population divergence. Genome Biol (2008) 2.00
Angiopoietin-2 levels are associated with retinopathy and predict mortality in Malawian children with cerebral malaria: a retrospective case-control study*. Crit Care Med (2012) 1.97
Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am J Trop Med Hyg (2012) 1.97
Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med (2009) 1.95
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One (2008) 1.90
Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop Med Hyg (2002) 1.88
Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. J Infect Dis (2005) 1.88
No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg (2012) 1.87
Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis (2005) 1.86
Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children. Am J Trop Med Hyg (2005) 1.86
The distribution and intensity of parasite sequestration in comatose Malawian children. J Infect Dis (2006) 1.85
Malaria: mechanisms of erythrocytic infection and pathological correlates of severe disease. Annu Rev Pathol (2007) 1.83
Identification of a conserved Plasmodium falciparum var gene implicated in malaria in pregnancy. J Infect Dis (2002) 1.81